NASDAQ$DH
Definitive Healthcare Corp · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results with revenue increasing by 12% year-over-year.
Definitive Healthcare reported Q2 2023 financial results with revenue of $61.0 million, a 12% increase year-over-year. The company's adjusted EBITDA was $17.2 million, representing 28% of revenue. The company is issuing financial guidance for Q3 2023 and full year 2023.
- Revenue was $61.0 million, an increase of 12% from Q2 2022.
- Net loss was ($11.6) million, or 19% of revenue.
- Adjusted Net Income was $12.4 million, compared to $8.8 million in Q2 2022.
- Adjusted EBITDA was $17.2 million, or 28% of revenue, compared to $16.3 million, or 30% of revenue in Q2 2022.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$61M
Forward guidance
The Company is issuing financial guidance for Q3 2023 and full year 2023. This guidance includes the dilutive effect of the acquisition of Populi and assumes no change in external conditions.
Tailwinds
- Revenue is expected to be in the range of $63.0 – $64.5 million, a 10-12% increase year over year.
- Adjusted Operating Income is expected to be in the range of $16.0 – $17.0 million.
- Adjusted EBITDA is expected to be in the range of $17.5 – $18.5 million.
- Adjusted Net Income is expected to be $9.5 – $10.5 million.
- Adjusted Net Income Per Diluted Share is expected to be $0.05 – $0.07 per share on approximately 156.9 million weighted-average shares outstanding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2023
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro